Suppr超能文献

POINT 试验中,小卒中与短暂性脑缺血发作后的残疾情况。

Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.

机构信息

From the Department of Neurology, University of Pennsylvania, Philadelphia (B.C.).

Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.E.).

出版信息

Stroke. 2020 Mar;51(3):792-799. doi: 10.1161/STROKEAHA.119.027465. Epub 2020 Feb 12.

Abstract

Background and Purpose- While combination aspirin and clopidogrel reduces recurrent stroke compared with aspirin alone in patients with transient ischemic attack (TIA) or minor stroke, the effect on disability is uncertain. Methods- The POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) randomized patients with TIA or minor stroke (National Institutes of Health Stroke Scale score ≤3) within 12 hours of onset to dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel versus aspirin alone. The primary outcome measure was a composite of stroke, myocardial infarction, or vascular death. We performed a post hoc exploratory analysis to examine the effect of treatment on overall disability (defined as modified Rankin Scale score >1) at 90 days, as well as disability ascribed by the local investigator to index or recurrent stroke. We also evaluated predictors of disability. Results- At 90 days, 188 of 1964 (9.6%) of patients enrolled with TIA and 471 of 2586 (18.2%) of those enrolled with stroke were disabled. Overall disability was similar between patients assigned DAPT versus aspirin alone (14.7% versus 14.3%; odds ratio, 0.97 [95% CI, 0.82-1.14]; =0.69). However, there were numerically fewer patients with disability in conjunction with a primary outcome event in the DAPT arm (3.0% versus 4.0%; odds ratio, 0.73 [95% CI, 0.53-1.01]; =0.06) and significantly fewer patients in the DAPT arm with disability attributed by the investigators to either the index event or recurrent stroke (5.9% versus 7.4%; odds ratio, 0.78 [95% CI, 0.62-0.99]; =0.04). Notably, disability attributed to the index event accounted for the majority of this difference (4.5% versus 6.0%; odds ratio, 0.74 [95% CI, 0.57-0.96]; =0.02). In multivariate analysis, age, subsequent ischemic stroke, serious adverse events, and major bleeding were significantly associated with disability in TIA; for those with stroke, female sex, hypertension, or diabetes mellitus, National Institutes of Health Stroke Scale score, recurrent ischemic stroke, subsequent myocardial infarction, and serious adverse events were associated with disability. Conclusions- In addition to reducing recurrent stroke in patients with acute minor stroke and TIA, DAPT might reduce stroke-related disability. Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT00991029.

摘要

背景与目的- 在 TIA 或小卒中患者中,与单独使用阿司匹林相比,联合使用阿司匹林和氯吡格雷可降低复发性卒中,但对残疾的影响尚不确定。方法-POINT 试验(新 TIA 和小卒中的血小板定向抑制)将发病 12 小时内的 TIA 或小卒中(NIHSS 评分≤3)患者随机分配至双重抗血小板治疗(DAPT)组(阿司匹林加氯吡格雷)与单独使用阿司匹林。主要结局测量指标是卒中、心肌梗死或血管死亡的复合指标。我们进行了事后探索性分析,以评估治疗对 90 天时整体残疾(定义为改良 Rankin 量表评分>1)的影响,以及当地研究者归因于指数或复发性卒中的残疾。我们还评估了残疾的预测因素。结果- 在 90 天时,1964 例 TIA 患者中有 188 例(9.6%)和 2586 例卒中患者中有 471 例(18.2%)残疾。DAPT 组与单独使用阿司匹林组的整体残疾发生率相似(14.7%与 14.3%;比值比,0.97[95%CI,0.82-1.14];=0.69)。然而,DAPT 组中与主要结局事件相关的残疾患者数量略少(3.0%与 4.0%;比值比,0.73[95%CI,0.53-1.01];=0.06),并且归因于指数事件或复发性卒中的残疾患者数量明显少于 DAPT 组(5.9%与 7.4%;比值比,0.78[95%CI,0.62-0.99];=0.04)。值得注意的是,归因于指数事件的残疾占这一差异的大部分(4.5%与 6.0%;比值比,0.74[95%CI,0.57-0.96];=0.02)。多变量分析显示,年龄、随后的缺血性卒中、严重不良事件和大出血与 TIA 患者的残疾显著相关;对于卒中患者,女性、高血压或糖尿病、NIHSS 评分、复发性缺血性卒中、随后的心肌梗死和严重不良事件与残疾相关。结论- 除了降低急性小卒中和 TIA 患者的复发性卒中外,DAPT 还可能降低与卒中相关的残疾。注册- URL:https://www.clinicaltrials.gov。唯一标识符:NCT00991029。

相似文献

4
Time to treatment and disability attributed to index stroke in the POINT trial.POINT 试验中与索引性卒中相关的治疗时间和残疾。
J Stroke Cerebrovasc Dis. 2024 Nov;33(11):107988. doi: 10.1016/j.jstrokecerebrovasdis.2024.107988. Epub 2024 Sep 1.

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验